retatrutide nejm 2023 obesity trial ly3437943 produces up to 30.3% weight loss in Phase 3 Phase 2 Trial of Retatrutide

A meta-analysis of 21 clinical studies showed a weighted mean difference in body weight of 2.9 kg (95% confidence interval [CI] 3.6 to 2.2) with the maximum dose of each one of the GLP-1RAs [43]

Semaglutide 2.4 mg once weekly is the latest approved GLP-1 RA for obesity management (2021) and results in 1517% mean WL through appetite reduction [11, 12]

A mice study published on Gut Microbes in February reported that Bifidobacterium longum NBM7-1 could activate GLP-1 and AMPK pathways which are both related to weight reduction

Rosenstock et al., 2023

Clinical studies have shown substantial weight loss with retatrutide, particularly at higher doses over longer treatment periods

Dosis Recomendada : Frmula Longevidad en 90 unidades/caja la dosis recomendada para una eficacia ptima en ayudar a equilibrar los niveles de glucosa en sangre y favorecer la gestin del peso, respondiendo a la tendencia creciente de consumidores preocupados por su salud